UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
11.77
+0.32 (2.79%)
Nov 21, 2024, 1:38 PM EST - Market open

UroGen Pharma Revenue

UroGen Pharma had revenue of $25.20M in the quarter ending September 30, 2024, with 20.87% growth. This brings the company's revenue in the last twelve months to $89.36M, up 15.64% year-over-year. In the year 2023, UroGen Pharma had annual revenue of $82.71M with 28.52% growth.

Revenue (ttm)
$89.36M
Revenue Growth
+15.64%
P/S Ratio
4.79
Revenue / Employee
$444,592
Employees
201
Market Cap
496.69M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202382.71M18.36M28.52%
Dec 31, 202264.36M16.32M33.96%
Dec 31, 202148.04M36.24M307.17%
Dec 31, 202011.80M11.78M65,450.00%
Dec 31, 201918.00K-1.11M-98.40%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Emergent BioSolutions 1.13B
Treace Medical Concepts 202.86M
Arcturus Therapeutics Holdings 160.40M
GRAIL 117.67M
Y-mAbs Therapeutics 84.55M
REGENXBIO 84.33M
Zevra Therapeutics 24.49M
OmniAb 20.41M
Revenue Rankings